ReviewCureus2019
Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Review in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives.International journal of molecular sciences · 2026Review
- Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease.Cardio-oncology (London, England) · 2026Article
- Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors.Journal of clinical medicine · 2025Article
- Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Cyclotron Production of Gallium-68 Radiopharmaceuticals Using thePharmaceutics · 2022Review
- Substitution of l-Tryptophan byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report.Journal of medical case reports · 2022Article
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2020Review
- Article
- Evaluation ofWorld journal of gastroenterology · 2020Article
- Long-Term Follow-Up of a Patient with Primary Presacral Neuroendocrine Tumor: A Case Report with Literature Review.The American journal of case reports · 2019Review
- Molecular Imaging and Therapy for Neuroendocrine Tumors.Current treatment options in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide incidence of neuroendocrine tumors (NETs) has been increasing. They are a very diverse group of tumors which are commonly found in the gastrointestinal and bronchopulmonary tracts. These tumors usually express somatostatin receptors. Therefore, somatostatin analogs are used for symptom relief as well as treatment. Of the many therapeutic options available, peptide receptor radionuclide therapy (PRRT) has been shown to be very promising. In January 2018, the Food Drug and Authority (FDA) approved
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.